NEW YORK, January 6, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting GlaxoSmithKline plc (NYSE: GSK), Centene Corp. (NYSE: CNC), WuXi PharmaTech Cayman Inc. (NYSE: WX), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
GlaxoSmithKline plc Research Report
On December 20, 2013, GlaxoSmithKline plc (GSK) and Medicines for Malaria Venture (MMV) jointly announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for tafenoquine, an investigational medicine for the treatment and relapse prevention of Plasmodium vivax (P. vivax) malaria. According to the Companies, the designation was granted based on the results from an international, multicentre, randomized Phase II clinical trial in more than 300 patients with uncomplicated P. vivax malaria. GSK reported that Tafenoquine is not yet approved or licensed for use anywhere in the world. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Centene Corp. Research Report
On December 20, 2013, Centene Corp. (Centene) announced that it will participate at the upcoming JP Morgan 32nd Annual Healthcare, to be held from January 13, 2014 to January 16, 2014, at the Westin St. Francis Hotel in San Francisco. The Company notified that it is schedule to make a presentation at the aforesaid conference on Monday, January 13, 2014 at 9:30 a.m. PT. Centene reported that a live audio webcast of the presentation and a replay of the same will be accessible through the Company's website under the Investor Relations section. The Full Research Report on Centene Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
WuXi PharmaTech Cayman Inc. Research Report
On December 23, 2013, WuXi PharmaTech Cayman Inc. (WuXi PharmaTech) announced that the five winners of the WuXi PharmaTech Life Science and Chemistry Awards were inducted as new members of the highly prestigious Chinese Academy of Sciences (CAS) and Chinese Academy of Engineering (CAE). WuXi PharmaTech reported that four former WuXi award winners - Professors Jiahuai Han of Xiamen University (2009 award winner), Xiaoming Feng of Sichuan University (2010 award winner), George Fu Gao of the Institute of Microbiology at the CAS (2011 award winner), and Jie He of the Oncology Hospital at the Chinese Academy of Medical Sciences (2011 award winner) were inducted at CAS, while Professor Guangji Wang of China Pharmaceutical University (2008 award winner) was inducted into the CAE. Dr. Ge Li, Chairman and CEO of WuXi PharmaTech said, "We are proud to see the excellent work of five of our former award winners recognized by the CAS and the CAE. Their groundbreaking scientific research provides great insights into diseases and holds promise for better cures. The inductions are very well deserved." The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Allscripts Healthcare Solutions, Inc. Research Report
On December 24, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) reported that its Allscripts Homecare software solution has been selected by Big Bend Hospice, Inc. (Big Bend Hospice) to improve the delivery of critical clinical information in the home, enabling the agency to focus on patient needs and better patient outcomes. Cathy Adkison, CEO of Big Bend Hospice, stated, "We chose Allscripts Homecare for its reliability, ease-of-use and its ability to integrate across platforms. Our ability to deliver the best possible care for patients relies on the efficiency and reliability of our IT systems. Allscripts provides an economical solution that helps us more easily manage our patients and our evolving operational needs." The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Immunomedics Inc. Research Report
On December 31, 2013, Immunomedics Inc. (Immunomedics) announced the issuance of U.S. patent no. 8,617,558 for additional claims under the patent family "Camptothecin-binding moiety conjugates," and U.S. patent no. 8,617,518 with additional claims for the patent family "Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules." Cynthia L. Sullivan, President and CEO of Immunomedics, stated, "This is a key patent for the protection of our antibody-drug conjugates patent family, of which IMMU-132, an anti-TROP-2-SN-38 conjugate, and IMMU-130, an anti-CEACAM5-SN-38 conjugate, constitute two of our most exciting new agents for solid cancer therapy." Sullivan added, "Both IMMU-132 and 130 are in Phase II clinical development and we plan to report results from these studies in the second quarter of 2014 at upcoming scientific and medical conferences." The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner